This systematic review and meta-analysis suggests that SGLT2 inhibitor use may be associated with improved cardiovascular outcomes, particularly reduced mortality and heart failure hospitalization, in cancer patients with diabetes receiving cancer therapies. Here, SLC5A2 is linked to cancer.